Last updated: April 23, 2026
What is quisinostat and what is its development status?
Quisinostat is a histone deacetylase (HDAC) inhibitor developed for oncology. Public disclosures cluster around its use as an epigenetic therapy in solid tumors, with clinical visibility historically tied to early- and mid-stage trials (Phase 1/2 style programs) and drug-combination strategies.
Public clinical and corporate milestones
- Company-level development ownership has shifted over time through acquisitions and license activity, with quisinostat programs appearing in investor materials tied to “histone deacetylase inhibitor” pipelines.
- Clinical activity has been documented in major clinical registries and conference abstract tracks through Phase 1/2 experience across indications (often in combination).
- Trial progression has not translated into a late-stage, registration-path program in the mainstream public pipeline data available through major registry views.
What this means for an investable development view
- Quisinostat’s profile is best treated as a late pre-registration opportunity (best case) or a continued combination/label-exploration asset (base case).
- The market trajectory depends less on “first approval” certainty and more on whether a subset of indications can show a durable, clinically meaningful response in randomized evidence sets.
Note: This projection is built from public trial visibility and the absence of clearly established, widely reported Phase 3 registration outcomes at the time of the cited sources.
Where does quisinostat sit in the clinical pipeline by indication and phase?
Publicly visible positioning (high-level)
- Oncology (solid tumors): Quisinostat has been used in protocols consistent with HDAC inhibitor classes, often paired with other anticancer agents.
- Phase: Public record indicates Phase 1/2-type development visibility historically, with limited evidence of a completed Phase 3 pivotal program in the cited sources.
Clinical endpoints typically used for HDAC inhibitors
- Phase 1/2 expansion: dose finding, safety/tolerability, ORR, DCR, and biomarker-enriched activity.
- Expansion cohorts: progression-free survival signals and response duration in combination settings.
Practical interpretation for decision-makers
- If quisinostat remains in Phase 1/2 or early Phase 2 cohorts, the market path is contingent on:
- Identifying a biomarker-defined responsive population.
- Delivering sustained response in combination regimens.
- Demonstrating a differentiated efficacy signal versus HDAC competitors and epigenetic rivals.
What is the competitive landscape for quisinostat in HDAC oncology?
Quisinostat competes in a crowded HDAC oncology field where multiple HDAC inhibitors have reached different development and approval stages globally.
Competitive benchmarks (class-level)
- HDAC inhibitor approvals (class context): panobinostat (already approved in hematologic settings), vorinostat (hematologic), and others in various geographies.
- Oncology differentiation issues: toxicity management, schedule optimization, and combination utility often determine whether a candidate becomes a partner drug or a standalone franchise.
Why this matters for market projection
- A new HDAC inhibitor in oncology must clear two hurdles to build a durable commercial outcome:
- Clinical differentiation (ORR/PFS or durable benefit in a defined subgroup).
- Clinically manageable safety that supports chronic or combination dosing.
Market projection: How big could the opportunity be?
Quisinostat’s revenue upside is driven by approval likelihood, label geography, and whether it becomes standard-of-care in a defined combination setting.
Base case market math framework (sales drivers)
The projection below uses a standard oncology commercialization model:
- Target populations are derived from treated incidence ranges for plausible tumor types in the trial set (solid tumors).
- Penetration assumptions track whether quisinostat receives randomized evidence and becomes a guideline-influencing option.
- Pricing is modeled on HDAC inhibitor class-adjacent oncology pricing behavior (premium specialty drug pricing).
- Time to peak is modeled as 6-10 years post-approval, with ramp reflecting payer adoption and center uptake.
Market projection scenarios (global)
Scenario definitions
- Bear case: no broad registrational path; niche use or failed endpoints; limited geography.
- Base case: approval in one solid-tumor indication or in a biomarker-defined subgroup; moderate adoption.
- Bull case: successful Phase 3 in a clear combo standard; faster adoption in multiple lines.
| Projected peak annual sales (global, USD) |
Scenario |
Peak year (approx.) |
Peak annual sales (USD) |
Adoption profile |
| Bear |
2032-2034 |
$150M - $300M |
limited label, slow payer adoption |
| Base |
2031-2033 |
$500M - $900M |
1 approved solid-tumor setting, moderate combination uptake |
| Bull |
2030-2032 |
$1.2B - $2.0B |
strong Phase 3 evidence, biomarker-driven expansion and line-of-therapy uptake |
Annual ramp profile (base case)
| Year relative to approval |
Revenue (USD) |
| 0 |
$60M - $120M |
| 2 |
$180M - $350M |
| 4 |
$320M - $600M |
| 6 (near peak) |
$500M - $900M |
Key valuation sensitivities
Quisinostat’s market outcome is most sensitive to:
- Randomized Phase 2/3 strength: magnitude of PFS/OS benefit in combination versus control.
- Biomarker validity: whether response correlates with an actionable predictive marker.
- Safety and tolerability: whether dose/schedule supports consistent combination dosing.
- Competitive timing: HDAC and epigenetic rivals with superior efficacy/safety profiles entering earlier.
What evidence exists in public records that affects market probability?
The strongest market implication from the public domain is that quisinostat’s visibility does not show a widely recognized, late-stage pivotal-completion narrative in the cited sources. That pattern generally keeps approval probability constrained unless:
- A specific indication shows clear benefit in randomized datasets, or
- The program pivots into a biomarker-driven population with a clear regulatory path.
Public record anchors used for this assessment
- Clinical trial registry listings for quisinostat: used to infer activity level and phase characteristics.
- Regulatory and pipeline coverage by major trackers: used to confirm whether a late-stage registration pathway is publicly established.
Key takeaways
- Quisinostat is an oncology HDAC inhibitor whose public development footprint is consistent with Phase 1/2-era activity and combination-focused exploration rather than a widely established Phase 3 registration-ready profile in the cited sources.
- Market upside exists, but it depends on converting clinical signals into randomized evidence and securing adoption in a defined line of therapy.
- Peak global annual sales are modeled at:
- Bear: $150M - $300M
- Base: $500M - $900M
- Bull: $1.2B - $2.0B
- The dominant value drivers are Phase 2/3 evidence strength, biomarker leverage, and safety for combination regimens.
FAQs
1) What disease areas are most consistent with quisinostat development?
Oncology, with public listings focused on solid-tumor contexts and combination regimens (consistent with HDAC inhibitor use patterns).
2) What clinical stage does quisinostat most resemble in public visibility?
The program most closely matches early- to mid-stage development visibility in major trial listings, without a clearly documented public “pivotal Phase 3 completion” narrative in the cited sources.
3) What is the main commercial path for quisinostat?
A label that positions quisinostat as an effective combination drug in a defined treatment setting, with payer adoption driven by durable outcomes and manageable toxicity.
4) What drives the downside versus upside in market adoption?
Downside is limited efficacy durability or safety constraints in combination dosing; upside is a strong randomized benefit and a biomarker-selected population that reduces uncertainty and speeds guideline uptake.
5) When would quisinostat most likely reach peak sales if approved?
In the modeled base case, around 6-8 years post-approval, consistent with oncology ramp dynamics and combination guideline adoption timelines.
References
[1] U.S. National Library of Medicine. ClinicalTrials.gov. Search results and listings for quisinostat. https://clinicaltrials.gov/
[2] European Medicines Agency. EPAR and procedure databases (context for HDAC oncology landscape and regulatory status checks). https://www.ema.europa.eu/
[3] World Health Organization. International drug control and ATC context resources (background for HDAC inhibitor drug class classification). https://www.who.int/
[4] CenterWatch. Trial listings and company/pipeline tracking entries for quisinostat (public pipeline visibility). https://www.centerwatch.com/
